Rapid Therapeutic Science Laboratories, Inc. Debt Conversion, Converted Instrument, Amount
Rapid Therapeutic Science Laboratories, Inc. reported Debt Conversion, Converted Instrument, Amount of $12.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-08-14
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-06-30 was $12.00K.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-03-31 was $112.66K.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for the quarter ending 2021-03-31 was $890.03K.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for the quarter ending 2020-12-31 was $1.53M, a 24.63% decline year-over-year.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for fiscal 2022 was $15.00K, a 98.31% decline from fiscal 2021.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for fiscal 2021 was $890.03K, a 66.34% increase from fiscal 2020.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $535.07K.
- Rapid Therapeutic Science Laboratories, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $2.03M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 9 month as first filed | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $12.00K 10-Q · filed 2023-08-14 | $124.66K derived: sum of 2 quarters · filed 2023-08-14 | |||
| 2023-03-31 | $112.66K 10-Q · filed 2023-08-14 | ||||
| 2022-12-31 | $15.00K 10-K · filed 2023-03-30 | ||||
| 2021-12-31 | $890.03K 10-K · filed 2023-03-30 | ||||
| 2021-03-31 | $890.03K 10-Q · filed 2022-11-10 | $2.42M derived: sum of 2 quarters · filed 2022-11-10 | $2.92M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2020-12-31 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | $2.03M derived: sum of 2 quarters · filed 2022-05-11 | $2.03M 10-Q · filed 2022-05-11 | $535.07K 10-KT · filed 2021-03-16 | $535.07K 10-K · filed 2022-03-16 |
| 2020-09-30 | $501.14K 10-Q · filed 2021-11-10 | $501.14K 10-Q · filed 2020-11-09 | |||
| 2020-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-13 | $2.03M derived: sum of 2 quarters · filed 2021-11-10 | $2.03M 10-Q · filed 2020-08-13 | $2.03M 10-KT · filed 2021-03-16 | |
| 2019-12-31 | $2.03M 10-Q · filed 2021-11-10 | $2.03M 10-Q · filed 2021-08-11 | $2.03M 10-Q · filed 2021-05-14 | $2.03M 10-K · filed 2022-03-16 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 |